CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that the Company's Chairmanand CEO John F. Crowley will be presenting a corporate overview, including the Company's continued progress with its global Phase 3 program for Fabry disease, at the Canaccord Genuity 30th Annual Growth Conference. Mr.
Individuals can listen to a live webcast of the presentation by logging on to the Investors section of the Amicus Therapeutics' web site, http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and neurodegenerative diseases. Amicus' lead program is in Phase 3 for the treatment of Fabry disease.
SOURCE Amicus Therapeutics
Subscribe to our Free Newsletters!
Craniosynostosis is a condition where the bones of the skull are fused together prematurely ...
Episiotomy is a surgical incision made in the perineum between the vaginal orifice and the anus ...
Stickler syndrome is a rare genetic disorder which causes multisystem disorders predominantly ...View All